This article is more than 5 years old. Information may no longer be current.
RegeneRx to receive ophthalmic wound healing patent in China
BETHESDA, Md. — RegeneRx Biopharmaceuticals has received official notice from the Chinese Patent Office that it intends to grant the company a patent for ophthalmic wound healing using Tß4, analogues and derivatives, RegeneRx announced in a press release.
Specifically, the patent will cover the use of Tß4 for either reversing or inhibiting eye degeneration associated with dry eye syndrome and certain surgical procedures including LASIK and PRK. The patent claims are based on data supporting the use of Tß4 for healing corneal and other wounds both in and around the eye, the release said.
Tß4's corneal wound healing properties are being tested in a RegeneRx-sponsored phase 2 clinical trial of diabetic patients undergoing vitrectomy; these patients often have corneal wound healing problems, according to the release.